LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Officer, Jane"
  2. AU="Roesch, Matthew R"
  3. AU=Brignole Michele
  4. AU="Mignosa, Carmelo"
  5. AU=Yates Laurel B
  6. AU="Allen, Quaylan"
  7. AU="Janjua, Muhammad Burhan"
  8. AU="Sejal M. Patel"
  9. AU="Yuchen Wang"
  10. AU="Williams, Gareth"
  11. AU="Garber, John J"
  12. AU="Seon-Ah Cha"
  13. AU="Hill, Hanna"
  14. AU=Panteli Michalis
  15. AU="Rocha, Jorge"
  16. AU="Zheng, Yifeng"
  17. AU="Simmons, Benno I."
  18. AU="Rivest, Jean"
  19. AU=Tian Henghe
  20. AU=Rahal Elias A.
  21. AU=Denholt Charlotte
  22. AU=Neale Benjamin M
  23. AU="Simon, Krzysztof"
  24. AU="Srivastava, Abhay Krishna"
  25. AU=Serrano Luis A
  26. AU="D'Orio, Vincent"
  27. AU="Davies, Neville"
  28. AU="Wise, J.C."
  29. AU="Mazer, Benjamin L"
  30. AU="Vellore J. Karthikeyan"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Measurement uncertainty in quantifying delta-9-tetrahydrocannabinol (THC) in blood using SPE and LC/MS/MS.

    Klu, Joyce K / Officer, Jane A / Park, Alexandra / Mudie, Roy / NicDaeid, Niamh

    Forensic science international

    2021  Band 322, Seite(n) 110744

    Abstract: A method for the quantitative analysis of delta-9-tetrahydrocannabinol (THC, the main active ingredient of cannabis) in whole blood using solid phase extraction and LC/MS/MS has been developed. A bottom-up approach with method validation data was used to ...

    Abstract A method for the quantitative analysis of delta-9-tetrahydrocannabinol (THC, the main active ingredient of cannabis) in whole blood using solid phase extraction and LC/MS/MS has been developed. A bottom-up approach with method validation data was used to evaluate and estimate the measurement uncertainty (MU) of the analytical method. The sources of uncertainty were identified using a cause and effect diagram. The contribution of each uncertainty component was estimated and were combined to derive the overall uncertainty of the analytical method. The combined uncertainty was estimated to be 0.131 μg/L (<7%). At a 99.7% confidence level, the expanded uncertainty was 0.393 μg/L for a THC concentration of 2 μg/L in a whole blood sample. The calculations not only enable the laboratory to quantify the uncertainty associated with a quantitative result, but can also be used to identify the sources of uncertainty and determine if the analytical method can be improved. An open access Measurement Uncertainty Calculator (MUCalc) software has been developed using the method described in this paper.
    Mesh-Begriff(e) Chromatography, Liquid ; Dronabinol/blood ; Forensic Toxicology ; Hallucinogens/blood ; Humans ; Mass Spectrometry ; Models, Statistical ; Solid Phase Extraction ; Substance Abuse Detection ; Uncertainty
    Chemische Substanzen Hallucinogens ; Dronabinol (7J8897W37S)
    Sprache Englisch
    Erscheinungsdatum 2021-02-22
    Erscheinungsland Ireland
    Dokumenttyp Journal Article
    ZDB-ID 424042-x
    ISSN 1872-6283 ; 0379-0738
    ISSN (online) 1872-6283
    ISSN 0379-0738
    DOI 10.1016/j.forsciint.2021.110744
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 1104: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Accuracy of substance exposure history in patients attending emergency departments after substance misuse; a comparison with biological sample analysis.

    Virmani, Ishita / Oteo, Alberto / Dunn, Michael / Vidler, Daniel / Roper, Clair / Officer, Jane / Hardy, Gareth / Dargan, Paul I / Eddleston, Michael / Cooper, Jamie G / Hill, Simon L / Macfarlane, Rebecca / Keating, Liza / Haden, Mark / Hudson, Simon / Thomas, Simon H L

    Clinical toxicology (Philadelphia, Pa.)

    2022  Band 61, Heft 1, Seite(n) 39–46

    Abstract: Context: Acute toxicity caused by illicit substance use is a common reason for emergency department (ED) presentation. Knowledge of the substances involved is helpful for predicting and managing potential toxicity, but limited information is available ... ...

    Abstract Context: Acute toxicity caused by illicit substance use is a common reason for emergency department (ED) presentation. Knowledge of the substances involved is helpful for predicting and managing potential toxicity, but limited information is available about the accuracy of patient-reported substance exposure. This study assessed the accuracy of the history of exposure in those reporting use of a single substance by comparison with those identified by detailed toxicological analysis, focusing on synthetic cannabinoid receptor agonists (SCRA).
    Methods: Adults (≥16 years) presenting between March 2015 and July 2021 to participating UK hospitals with toxicity after reporting use of a single illicit substance were included. Exposure details were documented from medical records and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry (HRAM LCMS). Sensitivity, specificity, and positive and negative predictive values of the exposure history were calculated by comparison with biological sample analysis ("gold standard").
    Results: Single substance exposure was reported for 474 (median age 33 years, IQR: 18 range 16-75, 80% males) patients. Analysis commonly identified multiple substances (Median 3, IQR 2-5). A history of exposure was documented for 121 of 151 patients where a SCRA or metabolite was detected on analysis (sensitivity 80.1%, 95% CI 72.9, 86.2%). Corresponding proportions were lower for 3,4-methylenedioxymethamphetamine (MDMA, 44/70, 62.9%., 95% CI 50.5%, 74.1%), heroin 41/108 (38.0% 95% CI 28.8-47.8%) and cocaine (22/56, 31.3%, 95% CI 20.9, 43.6%).
    Conclusions: Multiple undeclared substances were detected analytically in most patients reporting single substance use. Clinicians should be alert to the potential presence and toxicity of unreported substances when managing patients presenting after substance misuse.
    Mesh-Begriff(e) Adult ; Male ; Humans ; Adolescent ; Young Adult ; Middle Aged ; Aged ; Female ; Illicit Drugs/toxicity ; Substance-Related Disorders/diagnosis ; Substance-Related Disorders/epidemiology ; Cannabinoid Receptor Agonists ; Mass Spectrometry ; Emergency Service, Hospital ; Substance Abuse Detection/methods
    Chemische Substanzen Illicit Drugs ; Cannabinoid Receptor Agonists
    Sprache Englisch
    Erscheinungsdatum 2022-11-02
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 204476-6
    ISSN 1556-9519 ; 0009-9309 ; 0731-3810 ; 1556-3650
    ISSN (online) 1556-9519
    ISSN 0009-9309 ; 0731-3810 ; 1556-3650
    DOI 10.1080/15563650.2022.2131566
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 419: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.

    Craft, Sam / Dunn, Michael / Vidler, Dan / Officer, Jane / Blagbrough, Ian S / Pudney, Christopher R / Henderson, Graeme / Abouzeid, Ahmed / Dargan, Paul I / Eddleston, Michael / Cooper, Jamie / Hill, Simon L / Roper, Clair / Freeman, Tom P / Thomas, Simon H L

    Addiction (Abingdon, England)

    2022  Band 117, Heft 11, Seite(n) 2899–2906

    Abstract: Background and aims: The United Kingdom (UK) Psychoactive Substances Act (PSA), implemented on the 26: Design: Observational study.: Setting: Thirty-four hospitals across the UK participating in the Identification of Novel Psychoactive Substances ( ...

    Abstract Background and aims: The United Kingdom (UK) Psychoactive Substances Act (PSA), implemented on the 26
    Design: Observational study.
    Setting: Thirty-four hospitals across the UK participating in the Identification of Novel Psychoactive Substances (IONA) study.
    Participants: A total of 627 (79.9% male) consenting individuals who presented to participating hospitals between July 2015 and December 2019 with severe acute toxicity and suspected novel psychoactive substances exposure.
    Measurements: Toxicological analyses of patient samples were conducted using liquid-chromatography tandem mass-spectrometry. Time-series analysis was conducted on the monthly number of patients with and without analytically confirmed SCRA exposure using Poisson segmented regression.
    Findings: SCRAs were detected in 35.7% (n = 224) of patients. After adjusting for seasonality and the number of active sites, models showed no clear evidence of an upward or downward trend in the number of SCRA exposure cases in the period before (incidence rate ratio [IRR], 1.12; 95% CI, 0.99-1.26; P = 0.068) or after (IRR, 0.97; 95% CI, 0.94-1.01; P = 0.202) the implementation of the PSA. There was also no clear evidence of an upward or downward trend in non-SCRA exposure cases before (IRR, 1.12; 95% CI, 0.98-1.27; P = 0.105) or after (IRR, 1.01; 95% CI, 0.98-1.04; P = 0.478) implementation of the PSA.
    Conclusions: There is no clear evidence of an upward or downward trend in the number of patients presenting to UK hospitals with severe acute toxicity following analytically confirmed synthetic cannabinoid receptor agonist exposure since the implementation of the Psychoactive Substances Act.
    Mesh-Begriff(e) Cannabinoid Receptor Agonists/adverse effects ; Chromatography, Liquid ; Female ; Hospitals ; Humans ; Male ; Personality ; United Kingdom/epidemiology
    Chemische Substanzen Cannabinoid Receptor Agonists
    Sprache Englisch
    Erscheinungsdatum 2022-06-19
    Erscheinungsland England
    Dokumenttyp Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1141051-6
    ISSN 1360-0443 ; 0965-2140
    ISSN (online) 1360-0443
    ISSN 0965-2140
    DOI 10.1111/add.15967
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 551: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Acute toxicity following analytically confirmed use of the novel psychoactive substance (NPS) methiopropamine. A report from the Identification of Novel psychoActive substances (IONA) study.

    White, Joanna C / Wood, David M / Hill, Simon L / Eddleston, Michael / Officer, Jane / Dargan, Paul I / Dunn, Michael / Thomas, Simon H L

    Clinical toxicology (Philadelphia, Pa.)

    2019  Band 57, Heft 7, Seite(n) 663–667

    Abstract: Objective: ...

    Abstract Objective:
    Mesh-Begriff(e) Adolescent ; Adult ; Amphetamine-Related Disorders/complications ; Central Nervous System Stimulants/poisoning ; Female ; Humans ; Length of Stay ; Male ; Methamphetamine/analogs & derivatives ; Methamphetamine/poisoning ; Middle Aged ; Substance Abuse Detection/methods ; Substance-Related Disorders/complications ; Tandem Mass Spectrometry ; Thiophenes/poisoning ; United Kingdom ; Young Adult
    Chemische Substanzen 1-(2-thienyl)-2-(methylamino)propane ; Central Nervous System Stimulants ; Thiophenes ; Methamphetamine (44RAL3456C)
    Sprache Englisch
    Erscheinungsdatum 2019-01-24
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 204476-6
    ISSN 1556-9519 ; 0009-9309 ; 0731-3810 ; 1556-3650
    ISSN (online) 1556-9519
    ISSN 0009-9309 ; 0731-3810 ; 1556-3650
    DOI 10.1080/15563650.2018.1538519
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 419: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang